MediPharm Labs Plans To Uplist, Closes $75 Million Deal

MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) has applied to list its common shares on the Toronto Stock Exchange (TSX). MediPharm Labs continues to trade on the TSX Venture Exchange under the symbol “LABS”.

This follows the company’s announcement that it had closed its previously announced bought deal offering of 13,514,000 common shares in the capital of the company at a price of $5.55 per common share for aggregate gross proceeds of C$75 million.

“We are extremely pleased to be closing this successful and oversubscribed bought deal financing, a key milestone that significantly strengthens our balance sheet and supports continued growth,” said Pat McCutcheon, MediPharm Labs Chief Executive Officer. “This financing couldn’t come at a more opportune time as we look to roll-out further end-consumer cannabis products (including formulated oil bottles, gel caps, and vape cartridges) following the recent announcement of the final regulations authorizing additional cannabis extract-based products, which are expected to come into force this upcoming October. Our balance sheet positions us well to execute strategic international expansions to develop our business in new jurisdictions and secure a global supply chain.”

MediPharms said it plans to use the net proceeds from the offering to fund its ongoing capital expenditures at its Canadian and Australian facilities, for domestic and international expansions, research and development and general corporate purposes.

Deal Details

The offering was underwritten by a syndicate of underwriters led by Scotia Capital Inc., GMP Securities L.P. and BMO Nesbitt Burns Inc. MediPharm granted the underwriters an overallotment option to purchase up to an additional 2,027,100 Common Shares on the same terms and conditions, exercisable at any time, in whole or in part, for a period of 30 days following the closing of the Offering for over-allotment and market stabilization purposes. In the event the Over-Allotment Option is exercised in full, the aggregate gross proceeds of the Offering will be $86,253,105.

 

 

Debra Borchardt

Debra BorchardtDebra Borchardt

Debra Borchardt is the CEO, Co-Founder, and Editor-In-Chief of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Masters degree in Business Journalism from New York University.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 days

Executive Spotlight: Howard Lee, CEO & Co-founder of SōRSE Technology

@GreenMarketRpt – 3 days

cancels its plans to list on which had been expected today. “The Company is not proceeding wit…

Back to Top

You have Successfully Subscribed!